mod-4023
Recombinant proteinexperimental
Clinical trial activity
8 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
6
Phase 3
3
Phase 4
0
Earliest trial started Oct 1, 2009 (NCT01060722)
Timeline
Indications
Mechanism of action
- SomatotropinSupplementation
GH1 supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- mod-4023
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03874013 | Phase 3 | Dec 7, 2017 | National Center for Child Health and Development, Japan, Opko |
| NCT02968004 | Phase 3 | Dec 1, 2016 | Opko |
| NCT02418767 | Phase 1 | Jan 1, 2015 | Opko, WCCT Global |
| NCT01909479 | Phase 3 | Jun 1, 2013 | Opko |
| NCT02500316 | Phase 2 | Feb 1, 2013 | Hebrew University, Opko |
| NCT01592500 | Phase 2 | Feb 1, 2012 | Hebrew University, Opko |
| NCT01225666 | Phase 2 | Aug 1, 2010 | Opko |
| NCT01060722 | Phase 1 | Oct 1, 2009 | Opko, Tel Aviv University |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Opko | For profit | 8 | 8 | 3 | 2009 |
| Hebrew University | Academic/Hospital | 2 | 0 | 1 | 2012 |
| National Center for Child Health and Development, Japan | Government | 1 | 0 | 1 | 2017 |
| Tel Aviv University | Academic/Hospital | 1 | 0 | 1 | 2009 |
| WCCT Global | For profit | 1 | 0 | 1 | 2015 |
5 organizations
Page 1 / 1